REGN241129C1270000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Sanofi (SNY.US)/Regeneron (REGN.US) Dupilumab Injection approved again for clinical treatment of pure moss disease in China
A new clinical trial implied consent has been granted for the duperimabd injection declared by Sanofi (SNY.US).
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Regeneron Pharmaceuticals Unusual Options Activity
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock?
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
S&P 500, Dow Hit Records Right After Open | Live Stock
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 15% CAGR Over the Last Five Years
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters
Market Climbs, Bitcoin Close to $100k | Live Stock
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
Market Falls on Retail Results, Bitcoin Swells, All Eyes on Nvidia | Live Stock
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today